CEP certification confirms Brains Bio’s naturally-derived CBD pharmaceutical ingredient meets European Pharmacopoeia ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. Over the next few ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Cheap Stocks to Buy for High Returns in 2026. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released positive data from ongoing ...

The MarketWatch News Department was not involved in the creation of this content. HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter ...

The major pharmas are loaded up with trillions in firepower—but are sticking to mid-cap deals. One expert says it might be ...

DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including the Amex Biotechnology Index ETF (FBT), the ...

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 19% in the afternoon session after the company announced it agreed to acquire Amicus Therapeutics for approximately $4.8 billion ...

Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality ...

LNK01006 reflects Lynk Pharmaceuticals' medicinal chemistry expertise, incorporating a highly optimized scaffold engineered for target selectivity, metabolic stability, and CNS penetration. "We are ...